The GLP-1 Moat: Why Supply Infrastructure Is the New Efficacy
In the traditional pharmaceutical playbook, capital allocation follows an ingrained formula. Companies invest heavily in proving clinical efficacy and securing a dominant market. They treat the downstream supply chain as an operational detail to be resolved shortly before launch.
The GLP-1 market has overturned that paradigm. For modern blockbuster medicines, clinical data is no longer the sole differentiator. The market leader is not simply the company with the best molecule. It is the company that built the infrastructure to manufacture that molecule and deliver it to patients.
The Clinical and Executive Reality: Restructuring the Chain (Dr. Kotsianti)
The commercial leaders are no longer competing only in the laboratory. They are restructuring how a product reaches the patient.
Consider Eli Lilly. Through LillyDirect, it built a direct-to-patient channel outside the traditional distributor and pharmacy chain. When demand for tirzepatide outstripped autoinjector pen supply, Lilly used that channel to introduce single-dose Zepbound vials, a simpler presentation that drew on different fill-finish capacity.
In April 2026 it went further and launched Foundayo (orforglipron) through the same channel. Foundayo is a once-daily, chemically synthesised GLP-1 tablet that sidesteps the sterile fill-finish constraints of injectable peptides entirely. That was a supply decision made at molecule selection, years before launch.
The clinical cost of getting this wrong was visible throughout the shortage years. When branded supply could not meet demand, many patients turned to compounded and unregulated alternatives. Clinicians were left managing dosing errors and products of uncertain quality. A supply failure is not a commercial inconvenience. It is a patient-safety event, and it belongs on the medical governance agenda.
Lilly’s competitor took a more structural route.
The Industrial Reality of the Catalent Transaction (Hedley Rees)
The Industrial Reality of the Catalent Transaction
For two decades the industry treated sterile fill-finish as something to buy in, not something to own. The molecule was the crown jewel. Filling, stoppering, inspection and pen assembly went to whichever contractor had a line free. That logic held until demand for semaglutide went vertical.
The warning came early. A few months after Wegovy launched, deliveries stopped in late 2021 when the FDA found problems at Catalent’s syringe-filling plant in Brussels, and the plant shut again in August 2022. That is what a single point of failure looks like. The problem wasn’t a lack of API. It was a bottleneck in the last few metres of the chain, where capacity is scarce, validation is slow and qualifying an alternative takes years. (fiercepharma)
The structure of the deal is revealing. Novo Holdings paid $16.5bn to take Catalent private, and Novo Nordisk paid $11bn for just three fill-finish sites: Bloomington, Brussels and Anagni. Two-thirds of the price went on three plants. The market wasn’t valuing a CDMO. It was valuing scarce, licensed sterile capacity. Ownership was the remedy for a dependency designed in years earlier. (dcatvci)
Bloomington shows the limits of that remedy, because capacity can be bought but a state of control cannot. The FDA’s November 2025 warning letter records more than 20 mammalian-hair contamination deviations since August 2023, some in direct contact with product, and says affected batches were released to customers after Novo took ownership. After a year of remediation, the April 2026 re-inspection produced eight further observations and a second Official Action Indicated rating.
Other companies bore the cost. Regeneron’s applications for Eylea HD and odronextamab were held up. Scholar Rock’s SMA drug apitegromab was rejected in September 2025 solely because of the plant. It was approved a year later, after the company dropped Bloomington from its filing (Scholar Rock). One site’s quality system became the critical path for unrelated medicines in ophthalmology, oncology and rare disease.
The lesson isn’t that vertical integration was wrong. It’s that you cannot acquire your way out of a supply-architecture problem. A purchase transfers assets, people and liabilities. It doesn’t transfer process understanding, quality culture or control. Those have to be built, and the cheapest time to build them is long before anyone goes shopping for a factory.
Section 3 — Joint Analysis
Quality and Supply Must Be Built In Together (Joint Analysis)
Decades ago, the industry learned a hard regulatory lesson: quality cannot be inspected into a product at the end of the line. It must be designed into the process from the start.
Supply resilience deserves the same discipline. Stockpiles, emergency second-sourcing and late-stage acquisitions of capacity are ways for a system to insure itself against its own design. True resilience is decided far upstream, in nonclinical development and CMC, where budgets are tightest and the patient feels furthest away.
Section 4 — Hedley
The Upstream Solution
Two or three concrete examples would anchor the piece.
What does building supply into early development look like at the CMC level? Some possible directions:
• Simplifying formulation chemistry early.
• Standardised technology transfer protocols.
• Selecting scalable presentation and packaging formats during Phase I/II rather than at Phase III.
• Modality choice itself. The contrast between a synthesised small-molecule pill and an oral peptide that needs many times more API per dose may be a useful case.
[~ 300–400 words]
Conclusion — Dr Angeliki Kotsianti
The New Boardroom Mandate
If boards continue to scrutinise clinical endpoints while underfunding early process architecture, the resulting shortages are not accidents. They are foreseeable vulnerabilities built into a medicine’s design years before any hospital or pharmacy runs short.
Efficacy gets you to the starting line. Upstream process infrastructure determines who stays in the race.


I see Angeliki has a keen interest in Cancer recurrence
https://pubmed.ncbi.nlm.nih.gov/?term=Angeliki+Kotsianti
e.g. Prostate after Pfizer Jabs
https://geoffpain.substack.com/p/prostate-cancer-caused-by-endotoxin